Avience Biomedicals Sets IPO Launch for June 18: Everything You Need to Know!

Avience Biomedicals, a company based in Noida, Uttar Pradesh, is set to commence its IPO from June 18 to June 22, 2026, targeting a cap of INR 33.87 – 35.94 crores through the issuance of 1,728,000 shares priced between INR 196 and INR 208 per share. The medical consumables firm specializes in manufacturing in vitro diagnostic (IVD) products and medical devices, having gained prominence by developing essential diagnostic kits during the COVID-19 pandemic. With a lot size of 1,200 shares, the minimum investment for retail investors will be approximately INR 2,49,600. The shares are expected to list on the NSE EMERGE on June 25, 2026.

As for the grey market sentiment, specific figures regarding the IPO’s GMP (Grey Market Premium) are not available at this time. Nevertheless, early indicators suggest that there might be cautious optimism among investors, primarily due to the critical role Avience has played in diagnostic solutions amidst global health challenges. Being classified as a Startup and Small-Scale Industry under MSME frameworks, the company projects growth in revenue and net income over the fiscal years 2024 and 2025, further enhancing investor confidence.

For Indian investors, the Avience Biomedicals IPO presents an opportunity to invest in a company that aligns with the ongoing demand for advanced healthcare solutions. With the healthcare sector constantly evolving, Avience’s focus on affordable and high-quality diagnostic kits will likely resonate with investors keen on supporting innovative healthcare initiatives. Given the company’s promising financial performance projections, this IPO could be a strategic addition to a diversified investment portfolio, particularly for investors interested in the burgeoning life sciences space in India.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova IPO team.)